Details for Patent: 12,558,330
Which drugs does patent 12,558,330 protect, and when does it expire?
Patent 12,558,330 protects ENBUMYST and is included in one NDA.
This patent has eleven patent family members in nine countries.
Summary for Patent: 12,558,330
| Title: | Methods and compositions for treating edema refractory to oral diuretics |
| Abstract: | The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics. |
| Inventor(s): | Balasingam Radhakrishnan, Ben ESQUE, Wei Lin, Andrew Xian Chen |
| Assignee: | RESQ Pharmaceuticals LLC |
| Application Number: | US19/208,335 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 12,558,330
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corstasis Therap | ENBUMYST | bumetanide | SPRAY;NASAL | 219500-001 | Sep 12, 2025 | RX | Yes | Yes | 12,558,330 | ⤷ Start Trial | Y | INTRANASAL BUMETANIDE FOR THE TREATMENT OF EDEMA | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,558,330
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020397176 | ⤷ Start Trial | |||
| Brazil | 112022010879 | ⤷ Start Trial | |||
| Canada | 3160278 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
